Sugi Predict

Sugi Predict / Compounds / SCHEMBL1624027

SCHEMBL1624027

SCHEMBL1624027

N=C(N)c1cccc(C(=O)[C@@](Cc2ccccc2)(C(=O)O)N(C(=O)CN)c2ccccc2)c1.NC(=O)N1CCCC1

nearest known ligand 0.37

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 15/20 0.37
▸ PRSS1 P07477 11/20 0.37
▸ F2 P00734 6/20 0.37
▸ PLG P00747 1/20 0.35
▸ PLAU P00749 1/20 0.35
▸ PRSS2 P07478 2/20 0.34
▸ PRSS3 P35030 2/20 0.34
▸ HPN P05981 1/20 0.33
▸ HGFAC Q04756 1/20 0.33
▸ ST14 Q9Y5Y6 1/20 0.33
▸ LOXL2 Q9Y4K0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8127509 0.91 PRSS1 (0.41) F10PRSS1F2PLAUPRSS2
SCHEMBL1623556 0.82 SPHK1 (0.40) F10PRSS1F2PRSS2PRSS3
SCHEMBL8120426 0.77 ADRA2C (0.35) F10PRSS1F2PLGPLAU
SCHEMBL8125654 0.77 ADRA2C (0.35) F10PRSS1F2PLGPLAU
SCHEMBL8118334 0.75 PRSS1 (0.40) F10PRSS1F2PLAUPRSS2
SCHEMBL1623602 0.73 F2 (0.32) F10PRSS1F2PLAUPRSS2
SCHEMBL1624025 0.71 F10 (0.39) F10PRSS1F2PLGPLAU
SCHEMBL1624418 0.70 F10 (0.38) F10PRSS1F2PLGPLAU
SCHEMBL1623950 0.69 F2 (0.46) F10PRSS1F2PLGPLAU
SCHEMBL8121704 0.69 PLAU (0.36) F10PRSS1F2PLAUPRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928137-B2 Meta-benzamidine derivatives as serine protease inhibitors TULARIK LIMITED (GB) 2011-04-19 — — US disclosed
US-20070155790-A1 Meta-benzamidine derivatives as serine protease inhibitors LIEBESCHUETZ JOHN W 2007-07-05 — — US disclosed
US-7220781-B2 Meta-benzamidine derivatives as serine protease inhibitors TULARIK LIMITED (GB) 2007-05-22 — — US disclosed
EP-1009758-B1 META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2005-06-01 — — EP disclosed
US-20040143018-A1 Meta-benzamidine derivatives as serine protease inhibitors LIEBESCHUETZ JOHN WALTER (GB) 2004-07-22 — — US disclosed
US-6740682-B2 TREATMENT OF THROMBOTIC DISEASES, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY. TULARIK LIMITED (GB) 2004-05-25 — — US disclosed
US-20020055522-A1 Meta-benzamidine derivatives as serine protease inhibitors TULARIK LIMITED (GB) 2002-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055522-A1 Meta-benzamidine derivatives as serine protease inhibitors SERPINE1, PEPD, PRSS1 F10 378/4885PRSS1 3/4885F2 113/4885
US-20070155790-A1 Meta-benzamidine derivatives as serine protease inhibitors PEPD, SERPINE1, HPN F10 292/4885PRSS1 4/4885F2 103/4885
US-20040143018-A1 Meta-benzamidine derivatives as serine protease inhibitors SERPINE1, PEPD, PRSS1 F10 378/4885PRSS1 3/4885F2 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.